Effect of the observance of diurnal fast of Ramadan on duodenal ulcer healing with lansoprazole. Results of a prospective controlled study;Effet du respect du jeune diurne du Ramadan sur la cicatrisation de l'ulcere duodenal par lansoprazole. Resultats d'une etude prospective controlee

Gastroenterologie Clinique et Biologique

Volumn 21, Issue 11, 1997, Pages 820-822

  Mehdi, Abdelaziz ^a,b   Ajmi, Salem ^a  

^a SAHLOUL UNIVERSITY HOSPITAL   (Tunisia)

^b NONE   (Tunisia)

Author keywords

Duodenal ulcer; Fast; Lansoprazole; Ramadan

Indexed keywords

LANSOPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT; DRUG DERIVATIVE; OMEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; DUODENOSCOPY; DUODENUM ULCER; FEMALE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; RELIGION; TREATMENT OUTCOME; ULCER HEALING; COMPARATIVE STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; TIME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; DUODENAL ULCER; FASTING; FEMALE; HUMANS; ISLAM; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0030785418     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Rashed AH. The fast of Ramadan. Br Med J 1992;304:521-2.
2. Boey J, Wong J, Wong GB. A prospective study of operative risk factors in perforated duodenal ulcers. Ann Surg 1982;195:265-9.
3. Elashoff JD, Grossman MI. Trends in hospital admissions and death rates for peptic ulcer in the United States from 1970 to 1978. Gastroenterology 1980;78:280-5.
4. Griffin GE, Organ CH. The natural history of the perforated duodenal ulcer treated by suture plication. Ann Surg 1976;183:382-5.
5. Kurata JH, Honda GD, Frankl H. Hospitalization and mortality rates for peptic ulcers: a comparison of a large health maintenance organization and United States data. Gastroenterology 1982;83:1008-6.
6. Hakkou F, Tazi A, Iraqui L, Celice-Pingaud C, Vatier J. L'observance du Ramadan et son retentissement sur la sécrétion gastrique. Gastroenterol Clin Biol 1994;18:190-4.
7. Hongo M, Ohara S, Hirasawa Y, Abe S, Asaki S, Toyota T. Effect of lansoprazole on intragastric pH. Comparison between morning and evening dosing. Dig Dis Sci 1992;37:882-90.
8. Delhotal-Landes B, Cournot A, Vermerie N, Dellatolas F, Benoit M, Flouvat B. The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet 1991;suppl 3P:315-20.
9. Moules I, Garrett A, Blockleband D, Oliver S. Gastric acid inhibition by the proton pump inhibitor lansoprazole is unaffected by food. Br J Clin Res 1993;4:153-61.
10. Barradell LB, Faulds D. Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992;44:225-50.
11. Moules IK. Lansoprazole: pharmacokinetics and pharmacodynamics. Br J Clin Pract 1994;suppl:41-7.
12. Hawkey CJ, Long RG, Bardhan KD, Wormsley KG, Cochran KM, Christian J, et al. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. Gut 1993;34:1458-62.
13. Petite JP, Slama JL, Licht H, Lemerez M, Coste T, Andrieu J et al. Comparaison du lansoprazole (30 mg) et de l'oméprazole (20 mg) dans le traitement de l'ulcère duodénal. Gastroenterol Clin Biol 1993;17:334-40.